BridgeMD
New treatment option for Type 2 Diabetes
Official title Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion
ClinicalTrials.gov ID: NCT07398300
What this study is testing
What is GIP?
GIP is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for type 2 diabetes.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study investigates how the naturally occurring gut hormones GIP and GLP-1 influence whole-body glucose uptake and organ perfusion in humans. Using a state-of-the-art total-body PET-CT scanner, the study measures dynamic uptake of the glucose analogue 18F-FDG and blood flow using H₂¹⁵O across multiple organs during controlled elevations of plasma glucose and endogenous insulin secretion.
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 23 to 64. Healthy volunteers may be eligible.
You may be able to join if
- Sub-study 1 (Healthy individuals):
- Age 23-50 years
- BMI 20.0-26.9 kg/m²
- HbA1c \< 42 mmol/mol
- Able to provide informed consent Sub-study 2 - Participants with Type 2 Diabetes:
You likely can't join if
- (applies to all participants unless otherwise specified):
- Anaemia (haemoglobin below normal range)
- ALT \> 2× upper normal limit or any known hepatobiliary or gastrointestinal disorder
- Kidney disease (creatinine above normal range)
- Previous gastric or intestinal resection (except appendectomy or cholecystectomy) or major abdominal surgery (including bariatric surgery)
- For Sub-study 1: Type 1 or type 2 diabetes or HbA1c ≥ 42 mmol/mol
See the full eligibility criteria
- Sub-study 1 (Healthy individuals):
- Age 23-50 years
- BMI 20.0-26.9 kg/m²
- HbA1c \< 42 mmol/mol
- Able to provide informed consent Sub-study 2 - Participants with Type 2 Diabetes:
- Age 23-60 years
- Diagnosed with type 2 diabetes for ≥3 months
- HbA1c \> 53 mmol/mol
- Treatment with metformin only
- Able to provide informed consent Sub-study 2 - Healthy control participants:
- Age 23-64 years
- HbA1c \< 42 mmol/mol
- Able to provide informed consent
- (applies to all participants unless otherwise specified):
- Anaemia (haemoglobin below normal range)
- ALT \> 2× upper normal limit or any known hepatobiliary or gastrointestinal disorder
- Kidney disease (creatinine above normal range)
- Previous gastric or intestinal resection (except appendectomy or cholecystectomy) or major abdominal surgery (including bariatric surgery)
- For Sub-study 1: Type 1 or type 2 diabetes or HbA1c ≥ 42 mmol/mol
- Use of glucose-lowering medications other than metformin (Sub-study 2 only)
- Chronic obstructive pulmonary disease (Sub-study 2 only)
- Regular tobacco smoking or use of nicotine-containing products
- Claustrophobia
- Pregnancy, breastfeeding, or intention to become pregnant during the study period
- Initiation of special diets, major lifestyle changes, or weight loss \> 5% within 3 months prior to or during the study
- Any medication or physical/psychological condition that may interfere with participation (per investigator judgement)
- Inability to speak or read Danish
The study team makes the final eligibility decision.
Where it's taking place
- Copenhagen, Denmark
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 23 years to 64 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Copenhagen, Denmark. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.